Correction to: Infect Dis Ther 10.1007/s40121-021-00519-2
In the original publication of the article, figure 2 and the corresponding video were erroneously published. Fig. 2 and the video have now been corrected in the paper.
Fig. 2.
Summary of the MenACWY-CRM experience accrued during the first decade since its licensure. For more details, see video file 1 in the online/HTML version of the manuscript or follow the digital features link. *MenACWY-CRM inadvertently administered within 28 days prior to conception or during pregnancy. MenACWY-CRM is not indicated in pregnant women. MenACWY-CRM quadrivalent meningococcal vaccine against serogroups A, C, W and Y, conjugated to the nontoxic mutant of diphtheria toxin, HAV hepatitis A vaccine, HBV hepatitis B vaccine, Hib Haemophilus influenzae type b vaccine, IPV inactivated poliomyelitis vaccine, DTaP combined diphtheria, tetanus, acellular pertussis, PCV7 7-valent pneumococcal conjugate vaccine, PCV13 13-valent pneumococcal conjugate vaccine, Rotavirus rotavirus vaccine, MMR measles-mumps-rubella vaccine, V varicella vaccine, MMRV measles-mumps-rubella-varicella vaccine, Tdap tetanus-diphtheria-acellular pertussis vaccine, Td tetanus-diphtheria toxoid, HPV human papillomavirus vaccine, MenB Neisseria meningitidis serogroup B, 4CMenB multicomponent vaccine against meningococcal serogroup B, IMD invasive meningococcal disease
Footnotes
This article is published with digital features, including a plain language summary and video, to facilitate understanding of the article. To view digital features for this article go to 10.6084/m9.figshare.14980980.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.